{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:17:53Z","timestamp":1774451873107,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,2,9]],"date-time":"2005-02-09T00:00:00Z","timestamp":1107907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Some drugs currently used to treat tics in pediatric patients have drawbacks, including the risk of side effects. New therapeutic options with better safety profiles are needed. Levetiracetam is an antiepileptic drug with atypical mechanisms of action that might be beneficial for this indication. We evaluated the effects of levetiracetam on motor and vocal tics, behavior, and school performance in children and adolescents with tics and Tourette syndrome (TS). Sixty patients, \u226418 years of age, with tics and TS were enrolled in this prospective, open\u2010label study. The initial starting dose of levetiracetam was 250 mg\/day. The dosage was titrated over 3 weeks to 1,000 to 2,000 mg\/day. Clinical outcomes were assessed with the Clinical Global Impression Scale, Yale Global Tic Severity Scale, and Revised Conners' Parent Rating Scale. Behavior and school performance were also recorded. All 60 patients showed improvements based on all of the scales used, and 43 patients improved with regard to behavior and school performance. Levetiracetam was generally well tolerated. Three patients discontinued treatment because of exaggeration of preexisting behavioral problems. Levetiracetam may be useful in treating tics in children and adolescents. Given its established safety profile, levetiracetam is a candidate for evaluation in a well\u2010controlled trial. \u00a9 2005 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.20385","type":"journal-article","created":{"date-parts":[[2005,2,9]],"date-time":"2005-02-09T14:54:16Z","timestamp":1107960856000},"page":"714-718","source":"Crossref","is-referenced-by-count":68,"title":["Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome"],"prefix":"10.1002","volume":"20","author":[{"given":"Yasser","family":"Awaad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Michon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,2,9]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"261","article-title":"The epidemiology of tics and Tourette syndrome in children and adolescents","volume":"85","author":"Scahill L","year":"2001","journal-title":"Adv Neurol"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/01.wco.0000084232.82329.47","article-title":"Tics","volume":"16","author":"Pringsheim T","year":"2003","journal-title":"Curr Opin Neurol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5245(97)90126-7"},{"key":"e_1_2_5_5_2","first-page":"57","article-title":"Tourette disorder and ADHD","volume":"85","author":"Spencer T","year":"2001","journal-title":"Adv Neurol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(03)00060-6"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-003-0066-1"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307389901400508"},{"key":"e_1_2_5_9_2","first-page":"129","article-title":"Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives","volume":"57","author":"Silva RR","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(01)00262-4"},{"key":"e_1_2_5_11_2","first-page":"245","article-title":"Clonidine and clonazepam in Tourette syndrome","volume":"58","author":"Goetz CG","year":"1992","journal-title":"Adv Neurol"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00185-X"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704766"},{"issue":"4","key":"e_1_2_5_14_2","first-page":"42","article-title":"Use of levetiracetam in special populations","author":"French J","year":"2001","journal-title":"Epilepsia"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00052-2"},{"issue":"1","key":"e_1_2_5_16_2","first-page":"5","article-title":"Long\u2010term experience with levetiracetam","author":"Abou\u2010Khalil B","year":"2003","journal-title":"Epileptic Disord"},{"issue":"1","key":"e_1_2_5_17_2","first-page":"5","article-title":"Preliminary efficacy of levetiracetam in children","author":"Glauser TA","year":"2003","journal-title":"Epileptic Disord"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04053.x"},{"key":"e_1_2_5_19_2","first-page":"1005","article-title":"Effectiveness and tolerability of levetiracetam in 43 children and adolescents with epilepsy [in Spanish]","volume":"37","author":"Herranz JL","year":"2003","journal-title":"Rev Neurol"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3798(03)00041-2"},{"key":"e_1_2_5_21_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders DSM\u2010IV\u2010TR","year":"2000"},{"issue":"6","key":"e_1_2_5_22_2","first-page":"65","article-title":"Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses","author":"McConville BJ","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.5.599"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)01563-2"},{"issue":"7","key":"e_1_2_5_25_2","first-page":"43","article-title":"Use of levetiracetam (lev) in children under two years of age","author":"Frost MD","year":"2002","journal-title":"Epilepsia"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000091865.46063.67"},{"key":"e_1_2_5_27_2","volume-title":"Keppra (levetiracetam) prescribing information","year":"2004"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20385","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.20385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:01:24Z","timestamp":1760965284000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.20385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,9]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1002\/mds.20385"],"URL":"https:\/\/doi.org\/10.1002\/mds.20385","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,9]]}}}